Abbott Healthcare (ABT) under regulatory scrutiny in India amid an investigation into cough syrup abuse

Abbott Healthcare is facing regulatory scrutiny in India due to an investigation into the abuse of its cough syrup.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

SLB (SLB) Q4 2025 (USD): Adj. EPS 0.78 (exp. 0.74), Revenue 9.75bln (exp. 9.55bln)

ECB's Kocher says trade threats raise economic risks; would be cautious in adjusting policy pre-emptively against rising geopolitical risk

Abbott Healthcare (ABT) under regulatory scrutiny in India amid an investigation into cough syrup abuse

Citi's (C) to reportedly lay off more workers in March after bonus season

Indian Foreign Exchange Reserves (Jan/16) 701.36 (Prev. 687.19, Rev. From 687.19)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could impact the company’s reputation and potentially lead to financial ramifications, especially if it results in significant fines or operational restrictions. Keeping an eye on how this situation develops will be crucial, as it may affect investor sentiment toward the stock and the broader health care sector.

Related headlines

The whole workspace, free to try.

Try it free